{"id":144968,"date":"2025-06-03T06:37:05","date_gmt":"2025-06-03T06:37:05","guid":{"rendered":"https:\/\/teknomers.com\/en\/cancer-at-the-global-congress-in-chicago-innovations-that-inspire-hope-for-patients-teknomers\/"},"modified":"2025-06-03T06:37:07","modified_gmt":"2025-06-03T06:37:07","slug":"cancer-at-the-global-congress-in-chicago-innovations-that-inspire-hope-for-patients-teknomers","status":"publish","type":"post","link":"https:\/\/teknomers.com\/en\/cancer-at-the-global-congress-in-chicago-innovations-that-inspire-hope-for-patients-teknomers\/","title":{"rendered":"Cancer: At the global congress in Chicago, innovations that inspire hope for patients. Teknomers."},"content":{"rendered":"\n
\n

L\u2019Asco, the \u00a0world-renowned\u00a0 conference organized by the American Society of Clinical Oncology, is being held in \u00a0Chicago\u00a0 until Tuesday, June 3. This gathering is a crucial event for oncologists globally and showcases \u00a0promising advancements\u00a0 that bring hope to cancer treatment.<\/p>\n

What can we expect from \u00a0artificial intelligence\u00a0 (AI) in cancer care? Are there new treatment options on the horizon for the most dire cancer prognoses? Are we moving towards a \u00a0therapeutic de-escalation\u00a0? The ASCO conference, bringing together \u00a040,000 oncologists\u00a0 from around the world, is generating buzz about these intriguing questions and more.<\/p>\n

AI Transforming Imaging and Diagnosis<\/h2>\n

\u00a0Artificial Intelligence\u00a0 is playing an invaluable role in making cancer management more effective. From enhanced early diagnosis to personalized radiotherapy and liquid biopsies, the integration of AI is continuously pushing the boundaries in cancer care.<\/p>\n

For instance, a presentation at the conference highlighted that AI has improved the diagnostic accuracy of one of the most challenging breast cancer types, \u00a0HER2-positive cancer\u00a0, from \u00a066.7% to 88.5%\u00a0. Such advancements greatly reduce wait times for patients, allowing them to receive targeted treatment without unnecessary delays.<\/p>\n

A Breakthrough for Pancreatic Cancer?<\/h2>\n

Pancreatic cancer is notorious for its \u00a0poor prognosis\u00a0, with over \u00a014,000 new cases\u00a0 diagnosed annually in France alone, contributing to \u00a0400,000 global deaths\u00a0 each year. At ASCO, Ipsen announced results from a Phase 3 study on a new treatment that offers a \u00a0median survival\u00a0 of \u00a019.5 months\u00a0 among patients with metastatic pancreatic cancer\u2014significantly better than the typical survival rate of less than \u00a0one in five\u00a0 making it past the one-year mark.<\/p>\n

“This represents a significant advancement for a cancer that is notoriously difficult to treat, as data of this nature are rare,\u201d<\/em> remarked Sandra Silvestri, Executive Vice President at Ipsen, emphasizing that \u201cpatients usually live just \u00a04 to 6 months\u00a0 after being diagnosed with pancreatic adenocarcinoma.”<\/em><\/p>\n

The \u00a0Institut Curie\u00a0 also expressed optimism regarding hormone-dependent metastatic breast cancer. The institute is pioneering an approach to intercept treatment resistance through \u00a0liquid biopsies\u00a0, a promising development in the ongoing battle against this disease.<\/p>\n

On the front of \u00a0small cell lung cancer\u00a0, the \u00a0CHU de Toulouse\u00a0 has made headlines by taking part in an international Phase 3 trial evaluating a new treatment, \u00a0tarlatamab\u00a0, which invigorates the immune system to target cancer cells. Initial findings indicate that this therapy extends survival rates\u2014\u00a013.6 months\u00a0 compared to \u00a08.3 months\u00a0 with standard chemotherapy\u2014while also presenting fewer side effects.<\/p>\n

Myeloma: A Shift Away from Chemotherapy<\/h2>\n

Again, \u00a0CHU de Toulouse\u00a0 shines in its approach to managing multiple myeloma, a bone marrow cancer that impacts \u00a06,000 new patients\u00a0 each year. The \u00a0Midas clinical trial\u00a0, which involves \u00a0791 patients\u00a0 and is led by Professor Aurore Perrot, examines the potential of targeted \u00a0immunotherapy\u00a0 as a substitute for standard chemotherapy. Early results are promising: the treatment may alleviate the need for one or even both stem cell transplants in the most challenging cases.<\/p>\n

Hope for Effective Vaccines?<\/h2>\n

The \u00a0Institut Curie\u00a0 has announced “promising results for the world’s first \u00a0individualized\u00a0 ORL vaccine”<\/em>. This early-stage, Phase 1 study reveals that “none of the patients who received the vaccine experienced a relapse.”<\/em> This breakthrough could pave the way for \u00a0tailored vaccinations\u00a0 in treating various forms of cancer.<\/p>\n

Additionally, Curie is also exploring a \u00a0vaccine\u00a0 targeting pancreatic cancer, which could offer a new layer of hope for patients and families affected by this devastating illness.<\/p>\n

With the convergence of \u00a0innovative technologies\u00a0 and \u00a0cutting-edge research\u00a0, the advancements revealed at ASCO 2025 underscore the potential shifts in how we view and treat cancer. As researchers and oncologists collaborate globally, the future of cancer care appears ever more hopeful, with promising therapies paving the way toward \u00a0better management\u00a0, enhanced survival rates, and a renewed sense of possibility for patients and their loved ones.<\/p>\n<\/div>\n


\n
General News – 2<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

L\u2019Asco, the \u00a0world-renowned\u00a0 conference organized by the American Society of Clinical Oncology, is being held in \u00a0Chicago\u00a0 until Tuesday, June 3. This gathering is a crucial event for oncologists globally and showcases \u00a0promising advancements\u00a0 that bring hope to cancer treatment. What can we expect from \u00a0artificial intelligence\u00a0 (AI) in cancer care? Are there new treatment […]<\/p>\n","protected":false},"author":1,"featured_media":144969,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36400],"tags":[],"class_list":["post-144968","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/144968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/comments?post=144968"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/144968\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media\/144969"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media?parent=144968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/categories?post=144968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/tags?post=144968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}